|
Health-Related Outcomes in Patients Who Were Previously Treated for Rhabdomyosarcoma Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or treatment with a real dr.. We aren't doctors. Always consult your mD on Health-Related Outcomes in Patients Who Were Previously Treated for Rhabdomyosarcoma conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Health-Related Outcomes in Patients Who Were Previously Treated for Rhabdomyosarcoma Clinical research trials and Health-Related Outcomes in Patients Who Were Previously Treated for Rhabdomyosarcoma medical trials occur in many of places across the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectiveness of new does drugs. The role of the studies / undertakings is to figure out certain human healthcare questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to locate treatments for all forms of circumstances, including Health-Related Outcomes in Patients Who Were Previously Treated for Rhabdomyosarcoma. Health-Related Outcomes in Patients Who Were Previously Treated for Rhabdomyosarcoma Clinical Trials and other clinical trials permit volunteers to get medical treatment options before they are available to the masses. Most times the human subjects acquire treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Health-Related Outcomes in Patients Who Were Previously Treated for Rhabdomyosarcoma clinical trial. Participants oftentimes recieve the finest healthcare available for their Health-Related Outcomes in Patients Who Were Previously Treated for Rhabdomyosarcoma condition. Dangers are a reality, nonetheless, and might include extra or frequent physician calls, health hazards (potentially life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "H" Clinical Trials Conditions > Health-Related Outcomes in Patients Who Were Previously Treated for Rhabdomyosarcoma  Health-Related Outcomes in Patients Who Were Previously Treated for Rhabdomyosarcoma
Health-Related Outcomes in Patients Who Were Previously Treated for Rhabdomyosarcoma
For Condition: Quality of Life,previously treated childhood rhabdomyosarcoma,long-term effects secondary to cancer therapy in children
Status: Completed
Sponsor(s): National Cancer Institute (NCI) , Children's Cancer Group
Synopsis: RATIONALE: Cancer treatment may have risks that affect health outcomes later. It is not yet known what health outcomes may be related to previous treatment for rhabdomyosarcoma. PURPOSE: Study to determine health outcomes in patients who have survived 5 years after receiving treatment for rhabdomyosarcoma on the Intergroup Rhabdomyosarcoma Study Group protocols.
Details: OBJECTIVES: I. Determine the frequency of self reported health related outcomes in patients with rhabdomyosarcoma who survived 5 years from diagnosis after treatment on Intergroup Rhabdomyosarcoma Study Group (IRSG) protocols I, II, III, and IV pilot. II. Determine the mortality of these patients and compare this mortality to the general population, especially in the third and fourth decades of life. III. Determine treatment specific risks of developing a second malignancy following treatment of rhabdomyosarcoma and the potential genetic influences (family history of cancer). IV. Determine the association between decreased fertility/offspring and dose, schedule, and total dose of alkylating agents (especially cyclophosphamide) received during treatment and with selected genitourinary and paratesticular primaries. V. Determine the effect of the dose and location of therapeutic radiation for primary head and neck cancer on achieved final height. VI. Determine the association of therapy with doxorubicin (dose and age when received) with cardiac and vascular events. PROTOCOL OUTLINE: Patients (or parent or surviving family member) complete the baseline questionnaire plus other questionnaires (offspring, family history, other topic specific). Medical data is also collected from past records. PROJECTED ACCRUAL: Approximately 1600 patients will be accrued for this study.
Eligibility:
Study Type: Observational, Longitudinal
Minimum Age/Maximum Age: 5 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Prior registration on Intergroup Rhabdomyosarcoma Study Group; Study IRS-I, IRS-II, IRS-III, IRS-IV pilot, IRS-V, or IRS-V pilot, or one of the protocols of IRS-V (D9501, D9502, D9602) AND Survived for 5 years after diagnosis (may be deceased now) --Prior/Concurrent Therapy-- - See Disease Characteristics --Patient Characteristics-- - Age: 5 and over - Performance status: Not specified - Life expectancy: Not specified - Hematopoietic: Not specified - Hepatic: Not specified - Renal: Not specified
Total Enrollment:
Location and Contact Information:
Overall Study Official:
WilliamCrist, Study Chair, National Cancer Institute (NCI)
Additional Information:
Study ID Numbers: CDR0000066945; IRS-D9801,CCG-D9801,POG-D9801
Study Start Date:
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00003801
Other Previously Treated Childhood Rhabdomyosarcoma Studies:
1. Brain Function in Children Previously Treated on Clinical Trials POG-9605 and POG-9201
2. Study of Lung Function in Children Who Have Undergone Bone Marrow Transplantation
3. Health-Related Outcomes in Patients Who Were Previously Treated for Rhabdomyosarcoma
4. Genetic Study of Late-Occurring Complications in Childhood Cancer Survivors
Related Studies:
Other previously treated childhood rhabdomyosarcoma Clinical Trials
Other Clinical Trials
Other Clinical Trials
Health-Related Outcomes in Patients Who Were Previously Treated for Rhabdomyosarcoma
|
|
|
|
|
|
|
|
